Elsevier

Clinical Immunology

Volume 230, September 2021, 108814
Clinical Immunology

Full Length Article
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection

https://doi.org/10.1016/j.clim.2021.108814Get rights and content

Highlights

  • An understanding of antibody responses post SARS-CoV-2 natural infection is crucial for future health policy implementation

  • Anti-Spike-Receptor Binding Domain antibodies persisted in 96.8% (31 of 32) subjects at 14 months post natural infection

  • Patients reporting loss of smell and taste during the period of infection developed significantly higher antibody titers

  • Nucleocapsid protein-based antibody assays demonstrate higher false-negative rates and should be avoided in routine analysis

Abstract

Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies. Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein (NCP) and anti-spike-receptor binding domain (S-RBD) were used for sequential serological tests at different time points. The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed. Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months. Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers. Anti-NCP IgG seronegative patients(n=7) at 10 months, tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays. This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients.

Keywords

SARS-CoV-2
Covid19
Coronavirus
Humoral immunity
neutralizing antibodies

Cited by (0)

View Abstract